BIO-RAD LABORATORIES, INC. SEC Filings

Eva Anette Engelhardt, EVP and President, CDG at Bio-Rad Laboratories (BIO), reported changes in her holdings in two filings dated 09/05/2025–09/06/2025. On 09/05/2025 4,110 restricted stock units (RSUs) vested, each representing one share, and were reported as acquired. On 09/06/2025 an additional 1,152 RSUs were recorded as acquired (noted as a deemed execution/plan transaction), and separately 413 shares were disposed at a price of $295.43 on 09/06/2025. The filing shows resulting beneficial ownership counts after these transactions and is signed by Ms. Engelhardt on 09/09/2025. The RSUs vest over four years at 25% per year per the filing.

Bio-Rad Laboratories (BIO) Form 4: Courtney C. Enloe, EVP, General Counsel & Secretary, reported restricted stock units vesting and a small open-market sale. On 09/05/2025, 2,740 RSUs vested and were converted into shares; this increased reported holdings to 903.991 shares (which includes 6.5980 shares from the employee stock purchase plan). On 09/06/2025 an additional 768 RSUs were reported as acquired/vested. Also on 09/06/2025 the filing shows a disposition of 275 shares sold at $295.43 each, leaving 628.991 shares beneficially owned after the sale. The RSUs vest over four years at 25% per year.

Norman D. Schwartz, Chairman & CEO of Bio-Rad Laboratories (BIO), reported insider transactions related to Class A and Class B common stock. The filing shows vested restricted stock units converted into 3,455 Class A shares and a separate purchase of 1,528 Class A shares at $295.43 each, leaving him with 443,434 Class A shares direct ownership. The report also discloses 361,466 Class B shares held directly, 13,006 Class B shares held indirectly by spouse, and 4,060,054 Class B shares held indirectly by Blue Raven Partners, L.P. Restricted stock units vest over four years at 25% per year.

Rajat Mehta, Executive Vice President, Global Commercial Operations at Bio-Rad Laboratories, Inc. (BIO), reported grants of restricted stock units on 09/05/2025. The Form 4 shows two awards: 1,827 RSUs and 5,480 RSUs, each representing the contingent right to one share of Bio-Rad Class A common stock. Both grants have a $0 per-unit reported conversion price and are held directly by the reporting person. The 1,827 RSUs vest in four equal annual installments beginning on the first anniversary of the grant date; the 5,480 RSUs vest over four years at 25% per year on each annual anniversary. The filing is signed 09/09/2025.

Allison Schwartz, a director of Bio-Rad Laboratories (BIO), reported insider transactions on Form 4 covering September 1, 2025. The filing shows vesting-driven acquisitions: 147 shares of Class A common stock were added on vesting of restricted stock units at no cash cost and 31, 42, and 74 RSUs vested (representing rights to 31, 42 and 74 shares). Following the transactions, Ms. Schwartz beneficially owned 1,452 shares of Class A common stock directly. The report also discloses a sale of 55 shares at $297.88 each, reducing direct holdings to 1,397 shares. The filing reflects routine executive equity compensation and a small open-market sale.

Bio-Rad insider transaction summary: EVP and President, LSG Barry James reported transactions on 09/01/2025 involving Bio-Rad Laboratories Class A common stock (BIO). The filing shows 602 shares were acquired and added to his direct holdings following the vesting of restricted stock units, increasing his direct beneficial ownership to 748.555 shares. The filing also reports a disposition of 217 shares sold at $297.88 per share, leaving 531.555 shares after that sale. Separately, the report lists restricted stock unit activity: 178 units vested (converted to 0 shares remaining), 174 units vested and remain as 174 shares, and 250 units vested increasing total RSU-derived shares to 502. The transactions are documented on a Form 4 signed 09/02/2025.

Bio-Rad Laboratories EVP Colleen Corey reported RSU vesting on September 1, 2025. Three tranches of restricted stock units (254, 347 and 501) converted into 1,102 shares of Bio-Rad Class A common stock. To satisfy tax obligations, 398 shares were withheld at $297.88 per share. After these transactions, she directly holds 19,183 shares of Class A common stock and 1,349 restricted stock units.

Norman D. Schwartz, Chairman & CEO of Bio-Rad Laboratories (BIO), reported changes in his beneficial ownership on September 1, 2025. He acquired 6,353 Class A shares on vesting of restricted stock units and had 3,084 Class A shares disposed of at $297.88 per share. After these transactions he directly owned 441,507 Class A shares. The filing also reports direct ownership of 361,466 Class B shares and indirect holdings of 13,006 Class B shares (by spouse) and 4,060,054 Class B shares (by Blue Raven Partners, L.P.). Several restricted stock unit vesting events are noted, reflecting prior grants from 2021–2023 that vest in annual installments.

Bio-Rad Laboratories, Inc. filed a report describing an informational investor webinar focused on its Droplet Digital™ PCR (ddPCR™) product portfolio held on August 26, 2025. The webinar included a presentation and Q&A session with President and Chief Operating Officer Jon DiVincenzo and Chief Financial Officer Roop K. Lakkaraju. A live webcast and a replay, along with the slide presentation, are or will be available for up to a year in the Investor Relations section of the company’s website under “Events & Presentations.” The slide deck for the webinar is also provided as Exhibit 99.1, with the disclosure treated as furnished under Regulation FD rather than filed for liability purposes.